ENL.ASX: Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly Activities/Appendix 4C Cash Flow Report

Stock	Enlitic Inc (ENL.ASX)
Release Time	31 Oct 2025, 9:38 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Enlitic reports Q3 FY25 results, withdraws revenue guidance

Key Points

Record quarterly cash receipts of US$2.7m, total cash outflow of $800k
Record contract wins during the quarter: A$3.1m total contract value (+40.0% vs Q2 FY25)
Expect to contract with at least one large OEM in Q4 FY25

Full Summary

Enlitic, a medical technology software company leveraging artificial intelligence, has reported its Quarterly Activity Report and Appendix 4C for the three-month period ended 30 September 2025 (Q3 FY25). The company achieved record quarterly cash receipts of US$2.7m and a total cash outflow of $800k, compared to US$3.3m in the previous quarter. Enlitic signed a total of 40 new client agreements in Q3 FY25, including both migration technology contracts and Ensight software license agreements, with a total contract value of approximately A$3.1m, up 40.0% from the previous quarter. The company also advanced and expanded engagement with several existing and prospective OEM partners, which has increased the scope of existing and proposed projects and expanded its OEM-related deliverables. This has pushed out the project completion dates and the corresponding revenue recognition, leading Enlitic to withdraw its previous revenue guidance for FY25. However, the company remains strongly positioned for scalable growth, with momentum across OEM and end-user demand continuing to strengthen. Enlitic continues to demonstrate strong cost discipline and operational efficiency, with further implementation of cost savings contributing to its progress toward achieving operational cash flow break-even by the end of Q4 FY25.

Outlook

Enlitic remains focused on expanding the capability and reach of its product portfolio, strengthening its OEM partnerships, and accelerating adoption among healthcare providers. The company anticipates finalising at least one new OEM commercial agreement in Q4 FY25, further broadening its distribution footprint and accelerating integration of Enlitic's solutions into partner ecosystems. The company's expectation of additional commercial agreements remains unchanged and it anticipates operational break-even by the end of Q4 FY25.